STAT

Opinion: Landmark ruling sets precedent for parity coverage of mental health and addiction treatment

The Wit v. United Behavioral Health case sends insurers a clear message that there will be major consequences if they discriminate against individuals with mental health and substance use disorders.
A federal judge ruled that United Behavioral Health, which manages behavioral health services for UnitedHealthcare and other health insurers, created defective medical review criteria that wrongly rejected the insurance claims of more than 50,000 people seeking mental health and substance use disorder treatment.

For far too long, health insurers have been treating people with mental health and substance use disorders like second-class citizens. A federal court recently ruled that this must stop. Employers and regulators, take note.

The ruling came in the case of Wit v. United Behavioral Health (UBH). A federal court in Northern California found that UBH, which manages behavioral health services for UnitedHealthcare and other health insurers, rejected the insurance claims of tens of thousands of people seeking mental health and substance use disorder treatment based on defective medical review criteria. In other words, the largest managed behavioral health care company in the country was found liable for protecting its bottom line at the expense of its members.

What this case really boils down to, of course, is discrimination

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks